FESIA we are a technology-based company born with the aim of develop new products based in the FESa technology, a new concept of functional electrical stimulation.
The FESa technology is protected by a patent and two patent applications at international level and we have materialized it in several therapeutic and neuroprosthetic devices for people affected by neurological diseases.
It consists in a single electrodes pad (up to 32) which enables controlling each electrode independently or in groups improving muscle selectivity and reducing muscle fatigue of the patient.
Higher muscle selectivity during the stimulation: using a single electrodes pad, FES produces selective activation of desired muscles. This way muscle selectivity and functional performance are improved and muscle fatigue is reduced.
Automatic calibration: the automated algorithm uses a sensor feedback network as a reference for automatic calibration.
Easy integration: FESa technology based systems are capable for rapid hybrid system development. Available connectivity and processing power enables synchronization with other devices for producing advanced control paradigms.
Real-time adaptation: Having a high number of controllable stimulation parameters, the FESa technology is able to modify active stimulation patterns and location of ‘virtual electrodes’ for maintaining or improving the quality of artificially induced movement.
Patients have a higher autonomy and independence since they can use remotely the device with no external help.
Moreover, he can do the rehabilitation at home and that reduces the number of physician office visits, reducing transport costs and third party dependence.
Medical doctors will improve the quality of their services, since with our devices patients achieve more natural movements, and movements that are not possible with standard FES technology.
Moreover, they will provide a better patient monitoring. The system’s data logger monitors its use. These data can be downloaded to generate reports that are useful for the clinician to optimize future treatments.
HOSPITALS AND INSURANCE COMPANIES
Hospitals and insurance companies will have less number of patient visits meaning reduction of waiting lists and costs.